Halozyme, Takeda in arrangement to use former's drug delivery tech in Entyvio
Source: SeekingAlpha
2026-01-08 09:06:10 ET
More on Halozyme Therapeutics, Takeda Pharmaceutical
- Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade)
- Takeda: Lack Of Realistic Upside In Japanese Pharma
- Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript
- Takeda, XOMA ink new royalty agreement; amend existing deal
- Takeda posts late-stage trial win for oral plaque psoriasis therapy
Read the full article on Seeking Alpha
For further details see:
Halozyme, Takeda in arrangement to use former's drug delivery tech in Entyvio
Takeda Pharmaceutical Company Limited American Depositary Shares
NASDAQ: TAK
TAK Trading
1.48% G/L:
$18.23 Last:
742,229 Volume:
$18.15 Open:
TAK Latest News
March 02, 2026 02:00:00 am
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
February 24, 2026 09:35:00 am
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
TAK Stock Data
$57,107,745,653
3,115,826,299
N/A
157
N/A
Pharmaceuticals
Healthcare
JP
Chuo-ku
